VSTM Quote, Financials, Valuation and Earnings

iBio has a net margin of -82.56% compared to Verastem's net margin of -4444.57%. Verastem's return on equity of -120.71% beat iBio's return on equity of -148.3%.

Verastem has a consensus price target of $11.86, signalling upside risk potential of 82.7%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 48.76%. Given that Verastem has higher upside potential than iBio, analysts believe Verastem is more attractive than iBio.

Verastem has a beta of 0.237, which suggesting that the stock is 76.284% less volatile than S&P 500. In comparison iBio has a beta of -3.266, suggesting its less volatile than the S&P 500 by 426.584%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Verastem quarterly revenues are $10M, which are larger than iBio quarterly revenues of $175K. Verastem's net income of -$24M is lower than iBio's net income of -$4M. Notably, Verastem's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -82.56% compared to Verastem's net margin of -49.65%. Verastem's return on equity of -120.71% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Verastem has a consensus price target of $11.86, signalling upside risk potential of 82.7%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 496%. Given that NovaBay Pharmaceuticals has higher upside potential than Verastem, analysts believe NovaBay Pharmaceuticals is more attractive than Verastem.

Verastem has a beta of 0.237, which suggesting that the stock is 76.284% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Verastem quarterly revenues are $10M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Verastem's net income of -$24M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Verastem's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -82.56% compared to Verastem's net margin of -2357.27%. Verastem's return on equity of -120.71% beat Palatin Technologies's return on equity of --.

Verastem has a consensus price target of $11.86, signalling upside risk potential of 82.7%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1207.69%. Given that Palatin Technologies has higher upside potential than Verastem, analysts believe Palatin Technologies is more attractive than Verastem.

Verastem has a beta of 0.237, which suggesting that the stock is 76.284% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Verastem quarterly revenues are $10M, which are larger than Palatin Technologies quarterly revenues of $350K. Verastem's net income of -$24M is lower than Palatin Technologies's net income of -$7.8M. Notably, Verastem's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Reviva Pharmaceuticals Holdings has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Reviva Pharmaceuticals Holdings's return on equity of --.

Verastem has a consensus price target of $11.86, signalling upside risk potential of 82.7%. On the other hand Reviva Pharmaceuticals Holdings has an analysts' consensus of $14.80 which suggests that it could grow by 636.32%. Given that Reviva Pharmaceuticals Holdings has higher upside potential than Verastem, analysts believe Reviva Pharmaceuticals Holdings is more attractive than Verastem.

Verastem has a beta of 0.237, which suggesting that the stock is 76.284% less volatile than S&P 500. In comparison Reviva Pharmaceuticals Holdings has a beta of -0.120, suggesting its less volatile than the S&P 500 by 112.047%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reviva Pharmaceuticals Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Reviva Pharmaceuticals Holdings pays out -- of its earnings as a dividend.

Verastem quarterly revenues are $10M, which are larger than Reviva Pharmaceuticals Holdings quarterly revenues of --. Verastem's net income of -$24M is lower than Reviva Pharmaceuticals Holdings's net income of -$8.4M. Notably, Verastem's price-to-earnings ratio is -- while Reviva Pharmaceuticals Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for Reviva Pharmaceuticals Holdings. Usually stocks with elevated PS ratios are considered overvalued.